JP2023512175A5 - - Google Patents
Info
- Publication number
- JP2023512175A5 JP2023512175A5 JP2022542952A JP2022542952A JP2023512175A5 JP 2023512175 A5 JP2023512175 A5 JP 2023512175A5 JP 2022542952 A JP2022542952 A JP 2022542952A JP 2022542952 A JP2022542952 A JP 2022542952A JP 2023512175 A5 JP2023512175 A5 JP 2023512175A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- salt
- cancer
- hydrogen
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20155161 | 2020-02-03 | ||
| EP20155161.1 | 2020-02-03 | ||
| PCT/EP2021/052263 WO2021156180A1 (en) | 2020-02-03 | 2021-02-01 | [1,3]diazino[5,4-d]pyrimidines as her2 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023512175A JP2023512175A (ja) | 2023-03-24 |
| JP2023512175A5 true JP2023512175A5 (enExample) | 2024-02-08 |
| JP7626774B2 JP7626774B2 (ja) | 2025-02-04 |
Family
ID=69467427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542952A Active JP7626774B2 (ja) | 2020-02-03 | 2021-02-01 | ＨＥＲ２阻害薬としての［１，３］ジアジノ［５，４－ｄ］ピリミジン |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230131720A1 (enExample) |
| EP (1) | EP4100412A1 (enExample) |
| JP (1) | JP7626774B2 (enExample) |
| CN (1) | CN115052881B (enExample) |
| WO (1) | WO2021156180A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11608343B2 (en) | 2020-04-24 | 2023-03-21 | Boehringer Ingelheim International Gmbh | Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors |
| TW202214641A (zh) * | 2020-06-30 | 2022-04-16 | 美商艾瑞生藥股份有限公司 | Ｈｅｒ２突變抑制劑 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| EP4359082A1 (en) | 2021-06-26 | 2024-05-01 | Array BioPharma Inc. | Her2 mutation inhibitors |
| WO2023081637A1 (en) | 2021-11-02 | 2023-05-11 | Enliven Therapeutics, Inc. | Fused tetracyclic quinazoline derivatives as inhibitors of erbb2 |
| CN114031619A (zh) * | 2021-12-17 | 2022-02-11 | 山东汇海医药化工有限公司 | 一种图卡替尼中间体的制备方法 |
| CN114621221B (zh) * | 2022-03-12 | 2022-10-11 | 陕西海辰风扬医药科技有限公司 | 妥卡替尼关键中间体及其制备方法 |
| US20250206760A1 (en) | 2022-03-28 | 2025-06-26 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Nitrogen-containing heterocyclic compound, preparation method therefor, and pharmaceutical application thereof |
| CN117384162A (zh) * | 2022-05-17 | 2024-01-12 | 浙江文达医药科技有限公司 | 选择性her2抑制剂 |
| WO2024027695A1 (zh) * | 2022-08-04 | 2024-02-08 | 微境生物医药科技(上海)有限公司 | 作为her2抑制剂的化合物 |
| CA3263309A1 (en) | 2022-08-22 | 2024-02-29 | Iambic Therapeutics, Inc. | HER2 COMPOUNDS AND MODULATION METHODS |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| AR132562A1 (es) * | 2023-05-01 | 2025-07-16 | Enliven Inc | Formas polimórficas de (e)-1-((10s)-4-((4-([1,2,4]triazolo[1,5-a]piridin-7-iloxi)-2-fluoro-5-metilfenil)amino)-7,8,10,11-tetrahidro-9h-6,10-metanopirimido[4,5:5,6]pirido[3,2-b][1,4,7]oxadiazonin-9-il)-4-(dimetilamino)but-2-en-1-ona |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN116903615A (zh) * | 2023-06-21 | 2023-10-20 | 江苏丽源医药有限公司 | 一种妥卡替尼及其中间体的制备方法 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| CN122270275A (zh) | 2023-08-07 | 2026-06-23 | 科景特生物科学公司 | 用于fgfr抑制的化合物 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| CN121270563A (zh) * | 2024-07-01 | 2026-01-06 | 北京鞍石生物科技股份有限公司 | 稠环化合物及其制备方法和应用 |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19608588A1 (de) | 1996-03-06 | 1997-09-11 | Thomae Gmbh Dr K | Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| IL161908A0 (en) * | 2001-12-12 | 2005-11-20 | Pfizer Prod Inc | Quinazoline derivatives for the treatment of abnormal cell growth |
| WO2005044302A1 (en) * | 2003-11-06 | 2005-05-19 | Pfizer Products Inc. | Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer |
| DE602006021645D1 (de) | 2005-11-15 | 2011-06-09 | Array Biopharma Inc | Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten |
| US20170166598A1 (en) | 2014-05-13 | 2017-06-15 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| CA2949793C (en) | 2014-06-19 | 2024-02-27 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| US20210323976A1 (en) | 2015-05-13 | 2021-10-21 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| CN115057861A (zh) * | 2016-03-01 | 2022-09-16 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
| AU2018325442B2 (en) | 2017-08-31 | 2023-04-13 | Dana-Farber Cancer Institute, Inc. | Inhibitors of EGFR and/or HER2 and methods of use |
| CN109422755B (zh) * | 2017-09-01 | 2023-07-04 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、制备方法、中间体、组合物和应用 |
-
2021
- 2021-02-01 CN CN202180012676.0A patent/CN115052881B/zh active Active
- 2021-02-01 EP EP21703191.3A patent/EP4100412A1/en active Pending
- 2021-02-01 WO PCT/EP2021/052263 patent/WO2021156180A1/en not_active Ceased
- 2021-02-01 US US17/759,890 patent/US20230131720A1/en not_active Abandoned
- 2021-02-01 JP JP2022542952A patent/JP7626774B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023512174A5 (enExample) | ||
| JP2986546B2 (ja) | スマトリプタンを含有する組成物 | |
| ES2935800T3 (es) | Forma de dosificación oral de ketamina | |
| KR101673731B1 (ko) | 벰루페닙 및 mdm2 억제제의, 증식성 질환 치료용 복합 요법 | |
| EP3177311B1 (en) | Drug combinations of cabozantinib with proteasome inhibitor to treat multiple myeloma | |
| JP2021536453A5 (enExample) | ||
| ES2652670T3 (es) | Compuestos antifúngicos cristalinos | |
| JP2006523216A5 (enExample) | ||
| JP2025013684A (ja) | 重度腎機能障害を有する癌患者に対する治療方法 | |
| JP2019533660A5 (enExample) | ||
| TW202617156A (zh) | 用於治療進行性纖維化間質性肺病之新穎口服醫藥組合物及劑量療法 | |
| JP2022532766A5 (enExample) | ||
| JP4852605B2 (ja) | 放射線治療増強剤 | |
| JP2024525206A (ja) | 上皮成長因子受容体阻害剤の医薬組成物 | |
| JP2023531930A5 (enExample) | ||
| JP2023528896A5 (enExample) | ||
| CN120713908A (zh) | 帕布昔利布在黏膜恶性黑色素瘤中的应用 | |
| EP2425830A1 (en) | Synergistic drug combination for the treatment of cancer | |
| AU2008303504B2 (en) | Galenical formulations of Aliskiren | |
| KR20130078147A (ko) | 일정한 입도를 갖는 ４，５―디아릴―３（２ｈ）―퓨라논 유도체를 포함하는 약학 조성물 | |
| JP6937308B2 (ja) | キノリン誘導体またはその塩を含有する医薬組成物の製造方法 | |
| JP2022518288A5 (enExample) | ||
| CN113347975A (zh) | 用于治疗侵蚀性手骨关节炎的孟鲁司特 | |
| JP2021525758A5 (enExample) | ||
| CN120187730A (zh) | Prc2抑制剂的物理形式 |